Edison Inv. Res Weighs in on OTCMKTS:BPMUF FY2025 Earnings

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Research analysts at Edison Inv. Res issued their FY2025 earnings per share (EPS) estimates for shares of Basilea Pharmaceutica in a research report issued to clients and investors on Thursday, March 27th. Edison Inv. Res analyst J. Prakash anticipates that the company will post earnings per share of $4.76 for the year.

Basilea Pharmaceutica Price Performance

BPMUF stock remained flat at $54.00 during mid-day trading on Monday. Basilea Pharmaceutica has a 12-month low of $38.60 and a 12-month high of $54.00. The firm has a fifty day moving average price of $52.97 and a 200-day moving average price of $52.66. The company has a quick ratio of 3.27, a current ratio of 4.10 and a debt-to-equity ratio of 5.70.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.